CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
This light salad from Taking Cancer on Through Flavour is certainly big on taste - a perfect mix of salty, sweet, zesty and creamy, this dish is truly delicious.
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia